Private Label Kojic Acid Vitamin C Face Cream Manufacturer

The minimum order quantity for a private label kojic acid vitamin C face cream varies widely depending on whether the manufacturer is using a house base or your custom formula, and whether they specialize in small-batch cosmetic production. Most low-MOQ cosmetic contract manufacturers accept orders starting at 100 to 300 units for a pilot run. Some specialty labs will go as low as 50 units for a white-label formula with minimal customization, but those rarely include custom fragrance, custom actives concentrations, or novel packaging. For a fully custom formula with specific kojic acid dipalmitate and vitamin C derivative concentrations, pH-controlled manufacturing, and stability documentation, expect a realistic floor of 200 to 500 units on a first order. This is because the setup cost — formula development, batch record creation, challenge testing, and regulatory documentation — must be amortized over a minimum number of units before the manufacturer breaks even. MOQ is also driven by packaging. Airless pump components typically have their own supplier MOQ of 500 to 1,000 pieces, which may force your finished goods MOQ higher than the fill-and-label minimum would otherwise be. Some manufacturers partner with packaging aggregators to offer founders a 100-unit MOQ on airless pumps by pooling orders across multiple clients — ask specifically about this when quoting. Geography matters too. North American and European manufacturers tend to have higher MOQs (300–1,000) but offer tighter regulatory documentation. South Korean and Taiwanese OEM labs often accept 200-unit runs with strong GMP credentials and a deep bench of brightening-active experience, which makes them attractive for indie founders launching brightening SKUs. Indian and Chinese manufacturers may accept 100-unit runs but require more diligence on GMP certification verification. On AJ Cosmo Labs, you can filter manufacturers by MOQ range before you ever send a message, which saves the back-and-forth of discovering a lab's floor is 5,000 units after a week of email. Post your brief with your MOQ floor clearly stated and let vetted suppliers self-select into your inquiry. The most common mistake first-timers make is accepting the first MOQ quote as fixed. MOQ is negotiable, especially if you agree to pay more per unit on the pilot run, commit to a follow-on order in writing, or supply your own packaging components. A frank conversation about your growth trajectory can bring a 500-unit floor down to 200 for a brand that clearly has retail momentum.

Manufacturing cost for a private label kojic acid vitamin C face cream sits in a wide range: roughly $2.50 to $18 per finished unit depending on run size, active ingredient grade, packaging tier, and what services the manufacturer bundles in. Breaking this down by component helps founders budget more accurately. Raw materials are the biggest variable. Cosmetic-grade kojic acid dipalmitate (the esterified, more stable form) costs more than standard kojic acid but is significantly more stable in cream formulations and preferred by most formulators. L-ascorbic acid is the most potent vitamin C form but also the most expensive and least stable — many manufacturers steer founders toward ascorbyl glucoside or sodium ascorbyl phosphate, which are more forgiving in emulsion bases and cost somewhat less per kilogram. A 50 g cream with both actives at meaningful concentrations (1% kojic acid, 10–20% vitamin C derivative) may carry a raw material cost of $1.50 to $4.50 per unit before fill, labor, or packaging. Packaging is often 30–50% of total unit cost at low volumes. An airless pump in 30 ml frosted glass with a printed label can easily add $3.50 to $7.00 per unit at a 200-unit run. At 5,000 units, that same packaging component drops to $0.80 to $1.50 per unit. This is why cost-per-unit drops so sharply as volume increases. Manufacturing labor and overhead — the cost of the actual fill, mix, and QC — typically runs $0.80 to $2.50 per unit for cream formulations in North America and $0.30 to $1.00 in South and Southeast Asia. Stability testing, if not included in your per-unit quote, is usually priced as a flat fee of $500 to $2,500 for a 12-week accelerated study. Some manufacturers include a basic stability pass in their setup fee; third-party RIPT (Repeat Insult Patch Test) or dermatologist testing costs extra and ranges from $1,500 to $5,000 depending on panel size. On a 200-unit pilot run with custom packaging and full documentation, total landed cost of $14 to $18 per unit is realistic. At 1,000 units with streamlined packaging, $6 to $9 per unit is achievable. At 5,000+ units, well-optimized brands reach $3 to $5 per unit. A common mistake: founders compare per-unit quotes without confirming what each quote includes. One manufacturer's $5 quote may exclude stability testing, label design, regulatory dossier, and freight. Another's $8 quote may be all-in. Always request an itemized quote. The AJ Cosmo Labs app prompts suppliers to fill out standardized quote templates so you can compare apples to apples.

The total lead time from initial brief to finished goods for a private label kojic acid vitamin C face cream is typically 10 to 16 weeks when starting from a custom formula, or 6 to 10 weeks if you're building on a manufacturer's existing brightening base with minor customization. Here is how that timeline breaks down stage by stage: Weeks 1–2: Brief and supplier selection. This includes posting your project, receiving quotes, signing an NDA, and selecting a manufacturer. Founders who come in with a well-prepared brief (active concentrations, texture preference, target markets, packaging specs) cut this stage to 5 to 7 days. Vague briefs that require multiple rounds of clarification can stretch this to 3 weeks. Weeks 2–5: Formula development. The cosmetic chemist develops or adapts a base formula to hit your target active levels, adjust pH for kojic acid and vitamin C co-stability, and match your requested texture. Expect one to three rounds of prototype iterations. This stage typically takes 2 to 4 weeks depending on lab capacity and how many revisions are needed. If you approve the first prototype, you're at 2 weeks. If you request three rounds of changes, you're at 5 to 6 weeks. Weeks 5–9: Stability testing. A 12-week real-time study runs concurrently with a 4-week accelerated study (tested at 40°C/75% RH per ICH guidelines). Most manufacturers proceed to production once accelerated data is satisfactory, especially for a pilot run. For EU sales, you need a completed Cosmetic Product Safety Report (CPSR) which requires stability data, microbial challenge results, and a toxicologist sign-off. Allow 3 to 6 weeks for this documentation. Weeks 8–11: Packaging procurement. Airless pumps, glass jars, and printed components often have 4 to 8-week lead times from packaging suppliers. Experienced manufacturers start this procurement in parallel with formula development, but first-time founders often let this become a bottleneck. Weeks 11–14: Production and QC. The actual fill, label, and quality-control inspection for a 200 to 500-unit batch typically takes 1 to 2 weeks in-house. Third-party lab testing of the finished batch (microbial, heavy metals, preservative efficacy) adds another 1 to 2 weeks. Weeks 14–16: Shipping and receiving. Domestic shipments add 2 to 5 business days. International freight by air adds 1 to 2 weeks; sea freight adds 4 to 8 weeks. The most common mistake is underestimating the stability testing window and promising a launch date before data is in hand. Build your launch timeline backward from the required in-store or live date, and use a platform like AJ Cosmo Labs to coordinate milestones across manufacturer, packaging supplier, and regulatory consultant in one place.

Kojic acid is legal to sell in a face cream in the United States as a cosmetic ingredient, provided the product is positioned and labeled as a cosmetic — not a drug. The FDA does not have an approved OTC drug monograph for kojic acid, which means any claim that the product 'treats,' 'corrects,' or 'eliminates' hyperpigmentation or melasma triggers reclassification as an unapproved new drug, exposing the brand to enforcement action. Safe cosmetic claims include 'brightens the appearance of skin,' 'helps visibly reduce the look of dark spots,' and 'illuminates skin tone.' Concentration is not explicitly capped by FDA for cosmetics, but the industry norm is 1 to 2%; exceeding 2% raises safety questions that would need to be supported by toxicological data. In the European Union, kojic acid is more tightly regulated. The European Chemicals Agency (ECHA) and the Scientific Committee on Consumer Safety (SCCS) have scrutinized kojic acid for potential genotoxicity concerns. As of the most recent SCCS opinions, kojic acid has been found safe at up to 1% in face creams and up to 0.2% in products applied to the lip area, but the regulatory landscape is actively evolving. Brands selling into the EU must ensure their formula falls within the currently approved parameters and maintain an up-to-date CPSR. Manufacturers with EU export experience will already be tracking these amendments; always ask specifically about kojic acid compliance before signing a production agreement. In Japan and South Korea, kojic acid is approved as a quasi-drug brightening agent at up to 2%, making APAC markets more permissive for higher concentrations. Vitamin C (L-ascorbic acid and approved derivatives) presents fewer regulatory obstacles globally. It is widely accepted as safe in cosmetics and is included in most countries' positive or permitted ingredient lists. Prop 65 in California deserves mention: kojic acid is not currently on the Prop 65 list, but founders should re-verify this annually as the list is updated. Preservatives and fragrances in the formula may trigger disclosure requirements. The practical implication: have a regulatory consultant review your label claims and formula before production, not after. AJ Cosmo Labs connects founders with regulatory professionals alongside contract manufacturers, so you can address compliance in parallel with manufacturing setup rather than discovering a labeling problem after 500 units are already printed.

Kojic acid and kojic acid dipalmitate are both tyrosinase inhibitors derived from the same parent compound, but they behave very differently in a cream formulation, which directly affects which manufacturers can work with them and at what cost. Kojic acid (free form) is water-soluble and effective, but it is highly unstable. It oxidizes and turns dark brown or yellow when exposed to air, light, heat, or metal ions during manufacturing. This discoloration is not just cosmetically unacceptable — it often signals degradation of the active ingredient itself, reducing efficacy in the finished product. Manufacturers working with free-form kojic acid must use chelating agents (like EDTA or phytic acid), antioxidants (vitamin E, ferulic acid), nitrogen blanketing during mixing, and airtight, UV-opaque packaging to slow oxidation. Even with all these precautions, free-form kojic acid creams have shorter shelf lives (typically 12 to 18 months) and require strict storage conditions. Kojic acid dipalmitate (KAD) is an esterified, oil-soluble derivative. It is significantly more stable — it does not oxidize or discolor under normal manufacturing and storage conditions, and it is compatible with a wider range of formulation pH levels (up to pH 7, versus the 3.5 to 6 window needed for free-form). This makes it far easier to combine with other actives, including retinol and niacinamide, without pH conflicts. KAD is converted to free kojic acid on the skin via enzymatic hydrolysis, delivering the same brightening mechanism with better formulation stability. The trade-off: KAD requires a higher use concentration (typically 2–3%) to deliver the same active payload as 1% free-form kojic acid, and it costs more per kilogram. For a vitamin C combination specifically, KAD is almost always the preferred choice because vitamin C (especially L-ascorbic acid) is already demanding a low-pH environment that free-form kojic acid also requires — stacking two chemically demanding actives creates significant instability risk. KAD's pH flexibility makes the co-formulation far more tractable. When briefing a manufacturer — whether through a cold email or via the AJ Cosmo Labs app — specify whether you want free-form kojic acid or kojic acid dipalmitate. Many house bases use KAD precisely because it's more manufacturable, but some brightening enthusiasts specifically want free-form for formulation or marketing reasons. Knowing the difference ensures your brief is precise and prevents costly reformulation mid-project.

Finding a vetted private label cosmetic manufacturer for a small batch brightening cream requires more diligence than a simple Google search or Alibaba browse, because the specific combination of kojic acid, vitamin C, and low MOQ narrows the field considerably. Here is a structured approach. Start by defining your non-negotiables before you contact anyone: minimum GMP certification (ISO 22716 for cosmetics is the global standard), target MOQ, required active concentrations, destination markets (which determines documentation requirements), and your timeline. Founders who skip this step waste weeks in conversations with manufacturers who were never a fit. Vetting criteria to apply to every manufacturer shortlist: (1) Ask for their ISO 22716 or equivalent GMP certificate and verify the issue date — certificates expire and are sometimes shared past expiration. (2) Ask whether they have specifically manufactured products containing kojic acid and vitamin C, not just general brightening creams. Request example SDS or formula summaries (redacted is fine) to confirm real experience. (3) Ask for at least two references from founders at a similar scale — brands doing 200 to 1,000 units per run, not enterprise accounts. (4) Ask what stability testing infrastructure they have in-house versus what they outsource. (5) Confirm their minimum fill volume per batch — a manufacturer with a 100-kg minimum batch may not be a match for a 200-unit run of 50 ml jars. Traditional sourcing channels — trade shows like Cosmoprof, directories like Thomasnet or ICMAD member lists, LinkedIn outreach — are slow and unstructured. You often wait 5 to 10 business days for a response, then another week to get a quote, then discover the MOQ is incompatible. AJ Cosmo Labs was built specifically to solve this problem. Download the AJ Cosmo Labs iPhone app from the App Store, create a founder profile, and post a project brief describing your brightening cream requirements. The platform surfaces manufacturers who match your MOQ and active-ingredient expertise. You can message them directly, review their profile documentation, request sample quotes, and manage milestone payments — all without leaving the app. Vetted suppliers respond within the platform, and you can compare quotes side by side without managing a spreadsheet of email threads. The most common mistake first-timers make is selecting a manufacturer based on price alone. A $3.50 per-unit quote from an unaudited overseas lab with no stability data means you are absorbing all the regulatory and quality risk yourself. A slightly higher quote from a GMP-certified lab that includes a CoA (Certificate of Analysis), stability summary, and proper INCI labeling support is almost always the better investment for a brand with a future.

Adding SPF to a kojic acid vitamin C brightening cream is technically possible but dramatically increases regulatory complexity, cost, and lead time — and most low-MOQ contract manufacturers are not equipped to handle it. Here is what founders need to know before going down that path. In the United States, any product making an SPF claim is regulated as an OTC drug under the FDA sunscreen monograph (21 CFR Part 352, recently updated under the Sunscreen Innovation Act). This means the manufacturer must hold a Drug Establishment Registration with the FDA, follow cGMP drug manufacturing standards (21 CFR Parts 210/211 — stricter than cosmetic GMP), submit a Drug Facts label, and ensure the sunscreen active (zinc oxide, titanium dioxide, avobenzone, etc.) is used at concentrations and in vehicles covered by the existing OTC monograph. New sunscreen actives not on the monograph require a Time and Extent Application (TEA) — a multi-year FDA process. This is not something a small brand can navigate casually. In the EU, sunscreens are regulated as cosmetics under Annex VI of the EU Cosmetics Regulation 1223/2009, which maintains a positive list of approved UV filters at maximum concentrations. EU compliance is more accessible than US drug registration for SPF products, but still requires specific in-vitro or in-vivo SPF testing, broad-spectrum UVA testing (the EU requires a UVA PF of at least one-third of the labeled SPF), and a compliant CPSR. From a formulation standpoint, combining high-concentration ascorbic acid (which requires a low-pH environment) with SPF filters (many of which are pH-sensitive) and kojic acid creates a genuinely difficult formulation challenge. Physical filters like non-nano zinc oxide are more pH-tolerant but can create a white cast. Chemical filters may interfere with the stability or photostability of vitamin C derivatives. The practical advice for most indie founders: launch the brightening cream first as a cosmetic, build customer proof and revenue, then develop the SPF version as a separate SKU with a manufacturer that holds drug GMP registration. AJ Cosmo Labs can connect you with both cosmetic contract manufacturers for your initial launch and co-manufacturers experienced with SPF lines for the future — filter by capability when you post your brief in the app.